As the industry matures each year, so does the approach to investing in it. Yesterday, our managing partner Sergey Jakimov addressed this topic in his keynote, “Longevity Investing - Approach and Challenges,” at the 24th Investment Conference organized by CM-Equity AG. Sergey also shared insights about our partners at Longevity Science Foundation and Healthy Longevity Medicine Society, as well as our sister fund AniVC, launched by Garri Zmudze earlier this year. A big thank you to Michael Kott, Moritz Kott and Sophie Kott for the invite and opportunity. Last but not the least, great to connect with Aras Azadian of Avicanna Inc. (TSX:AVCN), Bernie Hertel of Skybioscience, Inc., our portfolio company Longenesis CEO Emil Syundyukov, and many more. We're looking forward to more insightful discussions and collaborations ahead.
LongeVC
Wagniskapital- und Private-Equity-Auftraggeber
Paradiso, Lugano 3.730 Follower:innen
We invest in an ageless future.
Info
We support early-stage biotech and longevity-focused founders that are changing the world. We help these companies gain industrial momentum, raise capital, and shape the future of biotech. Our approach is based on growing the whole ecosystem. We fund companies in complementary industrial sectors, empowering us to build a broad community of biotech innovators that can exchange their expertise and build on each other's successes.
- Website
-
http://www.longevc.com
Externer Link zu LongeVC
- Branche
- Wagniskapital- und Private-Equity-Auftraggeber
- Größe
- 2–10 Beschäftigte
- Hauptsitz
- Paradiso, Lugano
- Art
- Privatunternehmen
- Gegründet
- 2020
Orte
-
Primär
Via Calprino 18
Paradiso, Lugano CH-6909, CH
Beschäftigte von LongeVC
Updates
-
December is a great time for reflecting on the past year and making predictions for the year ahead. If you're a journalist working on a story about the future of biotech and longevity investing in 2025 and the upcoming trends, please get in touch with us at [email protected], or contact our team members Garri Zmudze, Sergey Jakimov, and Artem A. Trotsyuk. You can also meet Sergey Jakimov in Barcelona on December 4-5, where he will participate in this year's Health Tech Forward conference and speak on a panel about strategies for attracting health tech investment in 2025 and beyond, alongside Assaf Barnea from Sanara and Magda Krakowiak from EIT Health. For more information, visit https://lnkd.in/d8wY5jFT.
-
In the era of AI, scientific advancements are not limited to conventional laboratories or research facilities anymore. Platforms driven by AI enable scientists to engage in complex research by examining data, providing perspectives, and even collaborating on solutions. This broadening of access to science increases the pool of knowledge and speeds up progress by harnessing collective intelligence, promoting a new model in which science is more inclusive, agile, and innovative. On October 17, our Operating partner Artem A. Trotsyuk will share more about this topic in his “AI-driven Data for Scientific Breakthroughs: Empowering Citizen Science” keynote during Open Innovation in Life Sciences in Zurich, Switzerland. If you’d like to meet with Artem during the conference and his stay in Zurich, feel free to drop us DM or contact us at [email protected].
-
Our Managing partner, Sergey Jakimov, will be one of the speakers at CM-Equity AG’s 24th Investment Conference in Munich on October 2nd. He will discuss trends and share his knowledge and expertise on biotech and longevity investing. For more information, visit the event website at https://cm-equity.de/en/ and follow Michael Kott for more updates. If you would like to connect with Sergey during his time in Munich, feel free to drop us a DM or contact us at [email protected].
Entrepreneur & Active Investor in People and Megatrends, MK Family-Office, Host MK Investment Conference Munich, Optimtrader, Corporate Builder as Public Equity & Angel Investor
Last week was an important one for me: I learned a lot about #Longevity at the #ARDD2024 Conference in #Copenhagen, where the #WhoisWho from #BigPharma, #Topnoch #Biotech #Universities and its #Professors met #Startups like Ani Biome &Co. I had the pleasure to got into the venue with my #FO through LongeVC namely Sergey Jakimov and Garri Zmudze and their awesome team. Sergey Jakimov will be one of the keynote speakers at our 24th #InvestmentConference in Munich on Oct2nd and will educate the audience how #ActiveInvestors can invest in meanwhile one of the biggest megatrends of our times - #ExtendingYourLifespan #HealthyANDHappy PS: As you can see from Sergey's smiling face below - he lives what he is talking. After the ARDD Conference it is more clear to me than ever - to be able to change peoples lifes for the better makes happy and laughing on a day to day basis attributes substantially to personal health. Longevity is not a fashion trend, it is a personal life changing experience and an unstoppable growing global movement.
-
Breakthroughs in AI-powered biological models, precision genetic therapies, and novel interventions targeting the fundamental processes of aging are set to transform the future of aging and drug discovery. As longevity science moves from the lab to the clinic, cross-industry partnerships and regulatory shifts will play a critical role in reshaping healthcare and redefining the boundaries of human lifespan. If you missed this year’s Aging Research & Drug Discovery Meeting in Copenhagen, there were plenty of interesting topics, announcements, and insights shared during the conference. The use of novel models and tools for understanding aging was one of the widely discussed topics. Emad Moeendarbary from UCL gave an interesting talk on microfluidic organs-on-chips technology. Ed Boyden from Massachusetts Institute of Technology shared great insights on tools for analyzing, controlling, and simulating biological systems. Novo Nordisk revealed more about their focus on the longevity space, while Eli Lilly and Company publicly committed to becoming a longevity company, demonstrating a growing trend of big pharmaceutical companies and other major players entering this space. Notable insights were also shared by Peng Leong from BioAge Labs, David Glass from Regeneron Pharmaceuticals, Inc., Johan Luthman from Lundbeck, Alex Zhavoronkov from Insilico Medicine, and Matthew Wilson from Eli Lilly and Company on the pharma panel about preclinical development. Speaking of the industry’s potential, LongeVC’s Georg Nebgen gave a presentation about the trillion-dollar opportunity within the longevity and biotech sectors, followed by another great speech by Alex Zhavoronkov from Insilico Medicine. The final day of the conference was highlighted by a talk by Alexey Moskalev highlighting the potential of geroprotectors in mitigating the effects of aging, Anissa Anindya Widjaja sharing more details about her recent paper on IL11 inhibition, and closing talks by Steve Horvath from Altos Labs and LongeVC advisor Vadim Gladyshev from Harvard Medical School. We (finally!) saw many friendly faces in real life, including co-founders of our portfolio companies, Nika Pintar and Bruno Balen from Ani Biome and Vittorio Sebastiano from Turn Biotechnologies, who also delivered insightful talks about their recent developments. We also caught up with Anastasia Georgievskaya from Haut.AI and Emil Syundyukov from Longenesis. We’d like to thank everyone for the engaging conversations, inspiring meetings, and valuable insights shared. As a proud sponsor of this year's Aging Research and Drug Discovery Meeting, LongeVC eagerly anticipates reuniting with you in 2025. You can check our full summary here: https://lnkd.in/dDJFs6h9
-
Operating in stealth mode enables biotech firms to safeguard their intellectual property and concentrate on research and development without outside pressures. Nonetheless, this approach reduces visibility, making it challenging to attract top talent and investors. Companies need to find a balance between confidentiality and forming strategic partnerships to access resources, expand rapidly, and bolster their credibility in the market. Our Artem A. Trotsyuk recently discussed this topic and more with Willow Shah-Neville for her article in Labiotech.eu. You can read it in full here: https://lnkd.in/dzciYn8q
Stealth mode biotech startups: Everything you need to know
https://www.labiotech.eu
-
LongeVC invites ambitious graduate students (MS/PhD) and postdoctoral fellows to apply for our exclusive Venture Fellowship Program. This unique opportunity allows fellows to collaborate closely with our investment team, assisting in evaluating potential investments, participating in company pitches, and developing strategic initiatives. Fellows will also have the chance to network with industry experts and gain exposure to cutting-edge fields such as drug discovery and development, computational and synthetic biology, and genomic medicine. This is a part-time, remote, 6-month paid fellowship, with the potential for extension based on performance and mutual interest. Applications are due by September 15, 2024, with interviews taking place from September 23-27, 2024, and the fellowship starting on October 1, 2024. If you are interested, apply here: https://lnkd.in/dska2N64
-
The AI-driven biotech sector is likely experiencing a market correction, shifting from initial hype and inflated valuations to a more realistic understanding of the time and complexity needed for meaningful breakthroughs. Despite the current challenges, there is no doubt that AI has the potential to revolutionize drug discovery. In the short term, we should expect incremental progress rather than revolutionary breakthroughs. The long-term potential remains substantial, but realizing it may take longer than initially anticipated. LongeVC’s Artem A. Trotsyuk shared his insights on this topic in a recent in-depth Labiotech.eu article by Jules ADAM. You can read the full piece here: https://lnkd.in/dw88Xetq
Are we in an AI bubble? Biotech AI startups’ value plummet and leads to restructuration
https://www.labiotech.eu
-
LongeVC managing partner Sergey Jakimov recently shared his journey and thoughts on our space on the Innovation and Leadership podcast with Jess Larsen. The discussion delved into the evolving landscape of longevity and biotech investments, explored longevity science in depth, and covered Sergey's backstory—including how it led him to establish our fund. Tune in to the full episode here: https://lnkd.in/dAD2BnG6
Inside Longevity Fund's $250M Biotech Investments | LongeVC Founding Partner Sergey Jakimov
https://spotify.com
-
This year's Aging Research & Drug Discovery Meeting program is packed with amazing talks, panels, and keynote speeches from industry leaders worldwide. What better way to end an evening than with a panel discussing investment in the longevity and biotechnology space? Our general partner Garri Zmudze participated in the Investor's panel, expertly moderated by Lisa Melton from Nature Biotechnology Nature Portfolio. Joining them were Lars Hartenstein from McKinsey & Company Michael Baran from Pfizer, Petr Sramek from LongevityTech.fund and HealthyLongevity.clinic, Marie Kveiborg from Novo Nordisk Foundation, and Alex Zhavoronkov from Insilico Medicine. Thank you for this insightful conversation!